Ann: Botanix Presents at Fall Clinical Dermatology Conference, page-53

Good analysis regarding the SP,, except
early stage Bio buy out offers are a multiplier of the current SP, many Buyouts are circa 200% to 400% of the SP,, sure there are exceptions most of those are earning biotechs and Big Pharma buy them because they have the resources to scale them up, eg J & J have 11 thousand sales staff...

A 100% turn around on good news would only see BOT rise but still be below the years high considerably.

Most Investors here want to see greater returns than 10% to 20% but our insto would be grateful for a 20% return for "their shareholders"... so you can see the quagmire of the Insto with 139,000,000 shares to churn.

but as you rightly state ,,,,Time will Tell all